Dopamine quinone is substrate of the NRH: Quinone Reductase enzyme (QR2) in the retina. The capability of accumulates endogenous dopamine in a neural tissue explains the association of certain neuropsychiatric diseases with polymorphisms in the QR2 promoter that causes overexpression via loss of the capability to bind repressors. However, QR2 doubly reduce other small compounds present in neural and non-neural tissues, being its physiology tissue dependent. In this context, the function of the neurohormone melatonin and analogues in the active site of this multifunctional enzyme is discussed in this mini review. The flavoenzyme Ribosyldihydronicotinamide dehydrogenase (quinone), EC 1.10.99.2 (NRH: Quinone Reductase, QR2) is an unpredicted member of the quinone reductase family of phase II detoxifying enzymes [1] because its detoxifying activity produces reactive quinones and free radicals [2] . In addition, the natural QR2 cosubstrates are NRH (N-ribosyl-dihydronicotinamide) and NMH (N-methyl-dihydronicotinamide) [3] [4] [5] . This enzyme is inhibited by quercetin, resveratrol, benzo[a]pyrene [3] [4] [5] , some protein kinases inhibitors [6, 7] , antimalarial drugs [8] and many others synthetized analogues compounds [9, 10] . QR2 is able to doubly reduce quinones such as menadione, a synthetic vitamin K precursor, the coenzymes Q0-10
The flavoenzyme Ribosyldihydronicotinamide dehydrogenase (quinone), EC 1.10.99.2 (NRH: Quinone Reductase, QR2) is an unpredicted member of the quinone reductase family of phase II detoxifying enzymes [1] because its detoxifying activity produces reactive quinones and free radicals [2] . In addition, the natural QR2 cosubstrates are NRH (N-ribosyl-dihydronicotinamide) and NMH (N-methyl-dihydronicotinamide) [3] [4] [5] . This enzyme is inhibited by quercetin, resveratrol, benzo[a]pyrene [3] [4] [5] , some protein kinases inhibitors [6, 7] , antimalarial drugs [8] and many others synthetized analogues compounds [9, 10] . QR2 is able to doubly reduce quinones such as menadione, a synthetic vitamin K precursor, the coenzymes Q0-10 [11] and anti-cancer pro-drugs such as CB1954 [12] . The kinetics of this 24-kDa cytosolic flavoprotein proceeds via a double displacement mechanism [13] . Through this mechanism, FAD is reduced by the cosubstrate, which then diffuses out from the binding pocket, permitting occupation of the active site by the substrate. In this type of catalysis, the excess substrate competes with the cosubstrate, or vice-versa, resulting in the inhibition of the enzyme. Therefore, the effect of small compounds in QR2 catalysis is concentration dependent. The capability to accept a myriad of quinones and small compounds as substrates turn QR2 into a multifunctional enzyme. In mammals, QR2 is present in different tissues [1, 14] that contain different endogenous compounds. Additionally, each tissue is susceptible to be targeted by exogenous compounds with the ability to function as substrates for QR2 catalysis. Therefore, QR2 physiology appears to be tissue-dependent.
Dopamine plays a role in light-adapting events in retinal physiology [15] , whereas in the brain, attention, memory and other cognitive processes are regulated by dopamine [16] . A great achievement in the investigation of QR2 physiology was the finding that ortho-quinones such as dopa-quinone
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and dopamine-quinone function as substrates for QR2 catalysis in vitro. These catechol quinones are products of the oxidation of the L-dopa and dopamine, respectively. Therefore, the double reduction by QR2 results in the accumulation of dopamine [17, 18] . Currently, morphological findings agree in part with QR2 functioning in neural dopamine metabolism. The presence of QR2 immunoreactivity was reported in neural bodies of the normal cerebral cortex and hippocampus formation in humans and rodents [19] . In the retina, QR2 is present in human non-pigmented epithelial cells [20] , in developing neuronal whole retinas from chick [21] and in mouse retinal sections (our unpublished observations).
An attractive characteristic of QR2 is its ability to bind the small molecule melatonin [22] . This ancestral neurohormone signals the dark phase of the circadian rhythm; consequently, it has adaptive and therapeutic functions [23] . Melatonin and human QR2 crystallographic complexes show melatonin posed in two orientations. This is remarkable because the docking of the melatonin analogs 2-Iodomelatonin and 5-MCA-NAT have only one orientation in human QR2. One of the melatonin orientations is similar to 5-MCA-NAT, while the other is like the resveratrol inhibitor binding mode. The QR2 activity is inhibited by melatonin in vitro at a high IC 50 value (250 µM). This parameter was determined in competition assays using the cosubstrate NMH, the substrate menadione and melatonin, which exhibited competitive and uncompetitive inhibitory behaviour [22] . Melatonin is also a weak QR2 inhibitor when is used to counteract paraquat poisoning [24] . A relevant study suggesting that melatonin is a QR2 endogenous inhibitor was accomplished using mass spectroscopy. This study showed strong melatonin binding in the QR2 active site containing FAD in the oxidised state [11] . Nevertheless, the K d values for melatonin in binding assays were lower than the IC 50 values obtained for melatonin via in vitro and cellular assays [14] . These results are the foundation upon which melatonin has been considered a candidate for an endogenous cosubstrate [25] . We suppose that melatonin can be an endogenous QR2 cosubstrate or inhibitor, depending on the binding mode in QR2 active site, concentration and type of QR2 substrate available in the cell.
The same discrepancy between binding and activity in QR2 assays was observed when the QR2-selective melatonin analogue 5-MCA-NAT was investigated as an inhibitor [14, 26, 27] . However, the 5-MCA-NAT has only one orientation in QR2 active site, which is different of that exhibited by classical QR2 inhibitors as in human [22] as in chicken [27] . In fact, a cosubstrate role for 5-MCA-NAT in QR2 activity was observed in the retina. In these experiments, 5-MCA-NAT increased endogenous dopamine accumulation in the retinas from developing and post-hatched chicks, with an EC 50 = 2.41 pM; the same effect was observed by incubating retinas with the natural QR2 cosubstrate NMH (EC 50 = 182.60 nM). The presence of the 5-MCA-NAT (3 nM) increased the NMH potency (EC 50 = 4.19 nM), without affecting the endogenous dopamine accumulation. In contrast to incubating retinas with 5-MCA-NAT and NMH, the QR2 inhibitor benzo[e]pyrene, at IC 50 = 48.09 nM, diminished both control and NMH-stimulated endogenous dopamine accumulation. The binding mode and energy of the 5-MCA-NAT and benzo[e]pyrene in chick QR2 binding pocket reinforced the parameters obtained in experimental assays [27] . These results show that 5-MCA-NAT acts as a QR2 cosubstrate in situ. More importantly, the results show for the first time that QR2 activity accumulates dopamine in a neural tissue. Dopamine accumulation through the QR2 enzyme is in agreement with the previously observed QR2 overexpression in neuropsychiatric diseases that are associated with polymorphisms in the QR2 promoter [18] . Furthermore, the role of the QR2 enzyme in dopamine metabolism offers an additional foundation for developing selective QR2 inhibitors [10, 11] for the treatment of diseases that are characterised by an abnormal dopaminergic system. In the majority of these diseases, QR2 over activation is indicated not as a main etiopathological risk factor but as an aggravating factor of the basic pathology [18] . The overexpression observed in these diseases occurs by a polymorphism in the QR2 promoter that hampers the negative modulation of the NQO2 (the QR2 gene) [28] . In general, enzymatic overexpression through NQO2 polymorphisms has been related to familial and sporadic types of Parkinson's disease [18, 29] , Alzheimer's disease [19, 30, 31] , methamphetamine psychosis [32] and alcoholism [33] . In the retina, results demonstrating the ability of QR2 to accumulate dopamine are also physiopathologically important because this neural tissue is affected in Parkinson's disease [34] , and assessments of the retina has been proposed to estimate the progression of this neurodegenerative diseases in humans [35] .
The action of 5-MCA-NAT as a QR2 cosubstrate has been demonstrated in the retina, but the ability of melatonin to act as a cosubstrate in QR2 and accumulate dopamine in situ still needs to be demonstrated experimentally. Only one study shows that melatonin and 5-MCA-NAT have an antidepressant effect in mice during the tail suspension test [36] . This antidepressant effect is inhibited by prazosin in selective QR2 concentrations [36] and can be explained by 5-MCA-NAT and melatonin accumulating endogenous dopamine. Only melatonin functioning as QR2 cosubstrate explains an antidepressant effect that is inhibited by prazosin in a selective QR2 concentration. Though, neither melatonin nor 5-MCA-NAT is a suitable candidate as a QR2 inhibitor for the treatment of neuropsychiatric diseases associated with overexpression of the QR2 enzyme if these QR2 ligands reach neural tissues in pM/nM range, because at least 5-MCA-NAT is QR2 cosubstrates at these concentrations.
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